Estrella Immunopharma (ESLA) Non-Current Assets (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, little changed year-over-year from $1.5 million in Q1 2025, and little changed quarter-over-quarter from $1.5 million in Q4 2025.
Estrella Immunopharma (ESLA) Non-Current Assets (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Non-Current Assets for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets changed 0.0% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.0 million (up 33.33% YoY), while the FY2025 annual figure was $1.5 million, changed 0.0% from the prior year.
- Non-Current Assets steadied at $1.5 million in Q1 2026 per ESLA's latest filing, from $1.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $45.5 million in Q3 2022 and bottomed at $276187.0 in Q2 2023.
- Historically, Non-Current Assets has averaged $12.8 million across 5 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets grew 0.6% — and 2023, when it tumbled 99.39%.
- Estrella Immunopharma's Non-Current Assets stood at $9.7 million in 2022, then tumbled by 97.14% to $276187.0 in 2023, then jumped by 443.11% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
- Business Quant data shows ESLA's Non-Current Assets at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2023 | 276,187.00 |
| Mar 31, 2023 | 9.70 Mn |
| Dec 31, 2022 | 9.67 Mn |
| Sep 30, 2022 | 45.46 Mn |
| Jun 30, 2022 | 45.26 Mn |
| Mar 31, 2022 | 45.19 Mn |
| Dec 31, 2021 | 45.19 Mn |
| Sep 30, 2021 | 45.19 Mn |